Advertisement
BLFS vs CDNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLFS is a Hold and CDNA is a StrongBuy.
Momentum Indicator for BLFS turns positive, indicating new upward trend
BLFS saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 107 similar instances where the indicator turned positive. In 84 of the 107 cases, the stock moved higher in the following days. The odds of a move higher are at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in 235 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for BLFS moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 23 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for BLFS turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLFS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
BLFS broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BLFS entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. BLFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.497) is normal, around the industry mean (4.940). P/E Ratio (32.175) is within average values for comparable stocks, (36.759). BLFS's Projected Growth (PEG Ratio) (15.094) is slightly higher than the industry average of (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (16.779) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Aroon Indicator for CDNA shows an upward move is likely
CDNA's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 207 similar instances where the Aroon Indicator showed a similar pattern. In 181 of the 207 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 58 cases where CDNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CDNA as a result. In 83 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +8.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNA advanced for three days, in 238 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for CDNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Moving Average Convergence Divergence Histogram (MACD) for CDNA turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 36 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
CDNA broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CDNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.412) is normal, around the industry mean (64.051). P/E Ratio (32.037) is within average values for comparable stocks, (1.569). CDNA's Projected Growth (PEG Ratio) (48.410) is very high in comparison to the industry average of (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.146) is also within normal values, averaging (9.775).
BLFS | CDNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 48 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 95 | |
SMR RATING 1..100 | 56 | 34 | |
PRICE GROWTH RATING 1..100 | 36 | 34 | |
P/E GROWTH RATING 1..100 | 15 | 4 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CDNA's Valuation (97) in the Medical Specialties industry is in the same range as BLFS (99). This means that CDNA’s stock grew similarly to BLFS’s over the last 12 months.
CDNA's Profit vs Risk Rating (95) in the Medical Specialties industry is in the same range as BLFS (100). This means that CDNA’s stock grew similarly to BLFS’s over the last 12 months.
CDNA's SMR Rating (34) in the Medical Specialties industry is in the same range as BLFS (56). This means that CDNA’s stock grew similarly to BLFS’s over the last 12 months.
CDNA's Price Growth Rating (34) in the Medical Specialties industry is in the same range as BLFS (36). This means that CDNA’s stock grew similarly to BLFS’s over the last 12 months.
CDNA's P/E Growth Rating (4) in the Medical Specialties industry is in the same range as BLFS (15). This means that CDNA’s stock grew similarly to BLFS’s over the last 12 months.
| BLFS | CDNA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 86% |
| Advances ODDS (%) | 17 days ago 77% | 1 day ago 83% |
| Declines ODDS (%) | 21 days ago 83% | 14 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLFS’s FA Score shows that 1 FA rating(s) are green while CDNA’s FA Score has 1 green FA rating(s).
- BLFS’s FA Score: 1 green, 4 red.
- CDNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLFS’s TA Score shows that 2 TA indicator(s) are bullish while CDNA’s TA Score has 4 bullish TA indicator(s).
- BLFS’s TA Score: 2 bullish, 6 bearish.
- CDNA’s TA Score: 4 bullish, 4 bearish.
Price Growth
BLFS (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while CDNA (@Medical Specialties) price change was +5.76% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.77%. For the same industry, the average monthly price growth was -2.59%, and the average quarterly price growth was +7.55%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.12%. For the same industry, the average monthly price growth was -4.99%, and the average quarterly price growth was +43.90%.
Reported Earning Dates
BLFS is expected to report earnings on Nov 05, 2026.
CDNA is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-1.12% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BLFS and
Correlation & Price change
A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with RGEN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then RGEN could also see price increases.
| Ticker / NAME | Correlation To BLFS | 1D Price Change % | ||
|---|---|---|---|---|
| BLFS | 100% | N/A | ||
| RGEN - BLFS | 58% Loosely correlated | +1.39% | ||
| RVTY - BLFS | 51% Loosely correlated | +3.36% | ||
| A - BLFS | 50% Loosely correlated | +1.83% | ||
| DHR - BLFS | 47% Loosely correlated | -0.08% | ||
| ITGR - BLFS | 46% Loosely correlated | -0.04% | ||
More | ||||
CDNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with ADPT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To CDNA | 1D Price Change % | ||
|---|---|---|---|---|
| CDNA | 100% | +3.16% | ||
| ADPT - CDNA | 38% Loosely correlated | +1.96% | ||
| BLFS - CDNA | 38% Loosely correlated | N/A | ||
| ABT - CDNA | 37% Loosely correlated | -1.55% | ||
| CSTL - CDNA | 36% Loosely correlated | +3.06% | ||
| PSNL - CDNA | 36% Loosely correlated | +0.38% | ||
More | ||||